drugset / Trial / NCT02714504

Anti-mold Azole in the Prophylaxis for Invasive Fusariosis

NCT02714504

Completed 239 enrolled Federal University of Rio de Janeiro
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Patients admitted for autologous or allogeneic hematopoietic cell transplantation, induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid leukemia, or to receive immunosuppressive therapy for aplastic anemia will be screened with dermatologic examination. In the presence of any skin lesion in the extremities, direct exam and fungal culture will be performed. If these exams indicate the presence of Fusarium species, patients will receive anti-mold azole prophylaxis

Timeline

Start
2008-08
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Posaconazole Small molecule 200 mg
Subject Voriconazole Small molecule 200 mg